GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Phase 2

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-09-10

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 339

Registration Number: NCT01938430

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: LDV/SOF

First Posted Date: 2013-08-19

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 5

Registration Number: NCT01924949

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

Phase 2

Terminated

Conditions: Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections

Interventions: Drug: EVG
Drug: Background regimen

First Posted Date: 2013-08-15

Last Posted Date: 2018-08-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 31

Registration Number: NCT01923311

Locations: 🇿🇦
Be Part Yoluntu Centre, Cape Town, South Africa
🇮🇹
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇺🇬
Joint Clinical Research Centre, Kampala, Uganda

and more 8 locations

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: IMMU 130

First Posted Date: 2013-08-05

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Registration Number: NCT01915472

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2013-07-29

Last Posted Date: 2015-03-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 153

Registration Number: NCT01910636

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF
Drug: VEL
Drug: RBV

First Posted Date: 2013-07-29

Last Posted Date: 2018-11-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 323

Registration Number: NCT01909804

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

Completed

Conditions: HIV

First Posted Date: 2013-07-24

Last Posted Date: 2021-09-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 10577

Registration Number: NCT01906255

Locations: 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

Completed

Conditions: HIV

First Posted Date: 2013-07-18

Last Posted Date: 2020-07-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 172

Registration Number: NCT01902472

Locations: 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF
Drug: RBV

First Posted Date: 2013-07-11

Last Posted Date: 2015-05-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 127

Registration Number: NCT01896193

Locations: 🇷🇺
Institute of Nutrition of Academy of Sciences, Moscow, Russian Federation
🇷🇺
Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases, Saint-Petersburg, Russian Federation
🇷🇺
Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department, Moscow, Russian Federation

and more 13 locations

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Completed

Conditions: Limited Scleroderma
Diffuse Scleroderma

First Posted Date: 2013-06-19

Last Posted Date: 2014-04-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 29

Registration Number: NCT01881529

Locations: 🇦🇺
St Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy